Leonard Mazur

Media Exchange Group, Inc. is a digital media, technology, entertainment, wireless gamming and mobile publishing company. The company provides content in the form of mobile applications, digital media, web and broadcast products via its unique mix of acquisitions, on deck partnerships, license agreements, and joint venture revenue share arrangements. The company's current plan of operations consists of capitalizing on its digital sport cards delivery to youth and acquiring an operating business. Media Exchange Group has signed merger agreement with Intellicell Biosciences. The company was founded on March 8, 1999 and is headquartered in Los Gatos, CA

SENTÉ, Inc. provides skin care products. The firm's products include Daily Repair Complex, Neck Firming and Redness Control Complex creams. It offers dermal repair cream for people of various age groups and skin types for enhancing the skin tone, texture, elasticity, and overall appearance. The company serves customers through dermatologists and physicians in the United States. Sente was founded by Kleanthis G. Xanthopoulos and Marios Fotiadis in 2007 and is headquartered in Carlsbad, CA.

Intellicell Biosciences, Inc. develops stem cell derived pharmaceuticals. The company identified the technologies and laboratory process to target a portfolio of products and services in personalized medicine for the regenerative, preventative, and curative elements of age related disease states. The company was founded on June 3, 2011 and is headquartered in New York, NY.

Leonard-Meron Biosciences, Inc. develops and commercializes critical care products. It offers Mino-Lok, an antibiotic lock solution used to treat patients with catheter-related bloodstream infections. The company was founded by Myron Z. Holubiak in October 2013 and is headquartered in Cranford, NJ.

Citius Pharmaceuticals LLC markets aluminum license plate tags for automobiles. The company was founded on January 23, 2007 and is headquartered in Needham, MA.

Part of Citius Pharmaceuticals, Inc., Citius Oncology, Inc. is a late-stage pharmaceutical company focused on developing and commercializing targeted oncology therapies. The private company is based in Cranford, NJ. Citius Oncology's strategy centers on advancing innovative therapies with reduced development and clinical risks, leveraging competitive advantages supported by intellectual property and regulatory exclusivity protection. The company's lead product candidate is lymphir, an engineered il-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent ctcl, a rare form of non-Hodgkin lymphoma. The company was founded in 2021, and the CEO is Leonard L. Mazur.